Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126094622 | 12609462 | 2 | F | 20160715 | 20160812 | 20160801 | 20160817 | EXP | GB-MHRA-EYC 00142693 | GB-GLENMARK GENERICS (EUROPE) LTD.-2016GMK023802 | GLENMARK | 0.00 | Y | 0.00000 | 20160817 | OT | GB | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126094622 | 12609462 | 1 | PS | GABAPENTIN. | GABAPENTIN | 1 | Oral | 300 MG, TID | N | 77662 | 300 | MG | TID | ||||||
| 126094622 | 12609462 | 2 | SS | LANSOPRAZOLE. | LANSOPRAZOLE | 1 | Oral | 30 MG, OD | 0 | 30 | MG | QD | |||||||
| 126094622 | 12609462 | 3 | C | INSULIN | INSULIN NOS | 1 | Unknown | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126094622 | 12609462 | 1 | Neuralgia |
| 126094622 | 12609462 | 2 | Product used for unknown indication |
| 126094622 | 12609462 | 3 | Type 2 diabetes mellitus |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126094622 | 12609462 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126094622 | 12609462 | Acute kidney injury |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |